Related Experiment Video
Updated: Aug 24, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Rate-controlled intravenous voriconazole rapid desensitization in a patient with chronic pulmonary aspergillosis and
Eri Yasue1, Takunori Ogawa1, Yuto Mano1
1Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Abstract:
Oral triazoles, particularly itraconazole and voriconazole (VRCZ), are key antifungal agents for chronic pulmonary aspergillosis (CPA); however, hypersensitivity reactions to triazole antifungals can limit their use. We describe a 74-year-old man with CPA who developed immediate-type hypersensitivity reactions to both oral VRCZ and itraconazole. Because these oral formulations contain no excipient cyclodextrin, the reactions were attributed to the triazole drug substance, consistent with class cross-reactivity. After exhausting alternative antifungal options, VRCZ desensitization was undertaken. An intravenous route was selected as it allows precise dose titration and immediate interruption if required during rapid drug desensitization (RDD), with subsequent transition to oral therapy. The intravenous formulation of VRCZ additionally contains sulfobutyl ether β-cyclodextrin sodium, whose rapid infusion can provoke infusion-related reactions; the prescribing information therefore limits the infusion rate to ≤ 3 mg/kg/h. We modified a previously published RDD protocol to preserve the same cumulative target dose while strictly limiting infusion rate to ≤ 3 mg/kg/h, using only two diluted concentrations and adjusting the infusion rate alone. Desensitization was initiated at 0.05 mg (1/6000 of the planned dose) and escalated through 11 steps at 15-min intervals, with prolongation of the final step to remain within the infusion-rate recommendation. No hypersensitivity reactions occurred during desensitization. The patient subsequently tolerated maintenance intravenous VRCZ, which was switched to the same oral dose. Clinical symptoms improved, and follow-up imaging showed regression of the pulmonary lesion. Distinguishing triazole drug-substance hypersensitivity from excipient-related infusion risk, and controlling the infusion rate accordingly, may improve the safety of intravenous triazole desensitization.
Related Concept Videos
Cryptococcal Meningitis
Antifungal Agents
Dosage Regimens: Partial Pharmacokinetic Parameters
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Hypersensitivity Reactions: Cytolytic Reactions
Respiratory Syncytial Virus Disease